Efficacy News and Research

RSS
TAU researcher develops new antibodies to target and destroy cancer cells

TAU researcher develops new antibodies to target and destroy cancer cells

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Diluent choice affects neuromuscular block times

Diluent choice affects neuromuscular block times

DMARD not superior to oral therapy in long-term treatment of patients with JIA

DMARD not superior to oral therapy in long-term treatment of patients with JIA

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

Study reveals new evidence of trans-cranial bright light's effect to brain functions

Study reveals new evidence of trans-cranial bright light's effect to brain functions

Endo, Watson reach agreement to resolve two LIDODERM patent infringement lawsuits

Endo, Watson reach agreement to resolve two LIDODERM patent infringement lawsuits

ASCs promising source of cells for use in plastic surgery and regenerative medicine

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD

Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

FDA accepts CSL Behring’s 4-factor PCC BLA for standard review

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Lung in Oncology models for drug discovery launched by PRECOS

Lung in Oncology models for drug discovery launched by PRECOS

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics commences clinical study with oncolytic viruses

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Scientists develop super-sensitive test that could detect diseases earlier

Scientists develop super-sensitive test that could detect diseases earlier

Ultra-sensitive test can diagnose diseases in their earliest stages

Ultra-sensitive test can diagnose diseases in their earliest stages

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination program

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.